ciprofibrate

Small moleculeexperimental

Ciprofibrate is a fibrate that was developed as a lipid-lowering agent. — Wikipedia

Clinical trial activity

3 trials · 6 clinical orgs · 0 marketing orgs

Phase 1
0
Phase 2
1
Phase 3
1
Phase 4
2

Earliest trial started Feb 1, 2005 (NCT00350038)

Timeline

2010s

  1. Jan 1, 2018

    Earliest Phase 3 Sponsor(trial)

Indications

Approved for

Mechanism of action

Chemistry & pharmacology

Loading structure…

SMILES

Cc1ccc(/C(=C\CN2CCCC2)c2ccccn2)cc1.Cl
Mol. weight
314.86 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Racemic Mixture
Inorganic
No
Polymer
No

Oral

No

Parenteral

No

Topical

No

Sources

Also known as

  • 2-(4-(2,2-dichlorocyclopropyl)phenoxy)2-methylpropanoic acid
  • ciprofibrate
  • ciprofibrate
  • ciprofibrate
  • ciprofibrate
  • ciprofibrate
  • ciprofibrate
  • ciprofibrate
  • ciprofibrate
  • ciprofibrate
  • hyperlipen
  • lipanor
  • lipanor
  • modalim
  • modalim
  • modalim
  • oroxadin
  • oroxadin
  • win 35,833
  • win-35833
  • win-35833

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT03662984Phase 3Sep 19, 2018Maastricht University
NCT01480687Phase 4May 1, 2011Federal University of Rio de Janeiro, Rio de Janeiro State University
NCT00350038Phase 4Feb 1, 2005Bristol-Myers Squibb, Sanofi, Sanofi-Aventis
Showing 3 of 3 trials
Page 1 / 1

Organizations

Research & Development (6)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Bristol-Myers SquibbFor profit1012005
Federal University of Rio de JaneiroAcademic/Hospital1012011
Maastricht UniversityAcademic/Hospital1112018
Rio de Janeiro State UniversityAcademic/Hospital1112011
SanofiFor profit1112005
Sanofi-AventisFor profit1012005
6 organizations
Page 1 / 1